Purdue Pharma LP-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Purdue Pharma LP - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013449
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Purdue Pharma LP (Purdue) is a privately held, US-based pharmaceutical company which develops pharmacologic therapies for the treatment and management of pain. The company undertakes the research, development, manufacture and marketing of prescription medicines and over-the-counter (OTC) medicines and related healthcare products. Its major product categories include prescription opioids, sedatives (for sleep disorders), laxatives, antiseptics and dietary supplements. The company also conducts clinical studies on new investigational drugs and pharmaceuticals on the market. The company operates three facilities in North Carolina and New Jersey. It is a member of MundiPharma International Limited’s network of independent associated companies. Purdue is headquartered in Stamford, Connecticut, the US.

Purdue Pharma LP – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Purdue Pharma LP, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Purdue Pharma Acquires Rights to VM-902A from VM Pharma 12
Venture Financing 13
Kolltan Pharma Raises US$60 Million In Series D Financing 13
Partnerships 15
Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 15
University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 16
University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 17
Purdue Pharma to Form Joint Venture with AnaBios 18
Eisai Enters into Agreement with Purdue Pharma 19
Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 20
ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 21
Purdue Pharma Enters Into Co-Marketing Agreement With Transcept Pharma 22
Licensing Agreements 23
Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 23
Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 24
Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 25
Purdue Pharma Enters into Licensing Agreement with Exicure 26
Purdue Pharma Enters into Licensing agreement with AnaBios 27
Purdue Pharma Enters into Licensing Agreement with Medical Developments 28
Helsinn Signs Licensing Agreement with Purdue Pharma Canada 29
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 30
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 31
Purdue Pharma LP – Key Competitors 32
Purdue Pharma LP – Key Employees 33
Purdue Pharma LP – Locations And Subsidiaries 34
Head Office 34
Other Locations & Subsidiaries 34
Recent Developments 35
Corporate Communications 35
Jun 22, 2017: Dr. Craig Landau Appointed President and CEO Purdue Pharma L.P. 35
Legal and Regulatory 36
May 31, 2017: Attorney General DeWine Files Lawsuit Against Opioid Manufacturers for Fraudulent Marketing; Fueling Opioid Epidemic 36
Government and Public Interest 37
Mar 01, 2016: Purdue Pharma Led Collaborative Assessment Identifies Alarming Number of Errors in Commonly Used Online Drug Information Compendia 37
Product News 38
Jun 12, 2017: Consumer Research Drives New Packaging Updates for Colace and Senokot Occasional Constipation Relief Products 38
04/06/2016: Purdue Pharma Canada Expresses Disappointment in reaction to Health Canada decision to not proceed with proposed regulations requiring tamper resistance for Oxycodone 39
Appendix 40
Methodology 40
About GlobalData 40
Contact Us 40
Disclaimer 40

List of Tables
Purdue Pharma LP, Pharmaceuticals & Healthcare, Key Facts 2
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Purdue Pharma LP, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Purdue Pharma LP, Deals By Therapy Area, 2011 to YTD 2017 9
Purdue Pharma LP, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Purdue Pharma Acquires Rights to VM-902A from VM Pharma 12
Kolltan Pharma Raises US$60 Million In Series D Financing 13
Mundipharma Medical and Purdue Pharma Enter into Licensing Agreement with Esteve 15
University of Texas Health Science Center Enters into Co-Development Agreement with Purdue Pharma 16
University of Nebraska Medical Center and Purdue Pharma Enter into Agreement 17
Purdue Pharma to Form Joint Venture with AnaBios 18
Eisai Enters into Agreement with Purdue Pharma 19
Mundipharma and Purdue Pharma Enter into Development Agreement with Esteve 20
ElMindA Enters Into Agreement With Purdue Pharma To Develop New Pain Drugs 21
Purdue Pharma Enters Into Co-Marketing Agreement With Transcept Pharma 22
Purdue Pharma Canada Enters into Licensing Agreement with Klaria Pharma 23
Purdue Pharma (Canada) Enters into Licensing Agreement with BioDelivery Sciences International 24
Purdue Pharma Canada Enters into Licensing Agreement with Helsinn Group 25
Purdue Pharma Enters into Licensing Agreement with Exicure 26
Purdue Pharma Enters into Licensing agreement with AnaBios 27
Purdue Pharma Enters into Licensing Agreement with Medical Developments 28
Helsinn Signs Licensing Agreement with Purdue Pharma Canada 29
Grunenthal Enters Into Licensing Agreement With Purdue Pharma For IP Rights To Abuse-Deterrent Formulation Technology 30
Actavis Enters Into Licensing Agreement With Purdue Pharma For Generic OxyContin 31
Purdue Pharma LP, Key Competitors 32
Purdue Pharma LP, Key Employees 33
Purdue Pharma LP, Other Locations 34
Purdue Pharma LP, Subsidiaries 34

★海外企業調査レポート[Purdue Pharma LP-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Frequency Electronics Inc:企業の戦略・SWOT・財務情報
    Frequency Electronics Inc - Strategy, SWOT and Corporate Finance Report Summary Frequency Electronics Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Odebrecht SA:企業の戦略的SWOT分析
    Odebrecht SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Patterson-UTI Energy Inc (PTEN):企業の財務・戦略的SWOT分析
    Patterson-UTI Energy Inc (PTEN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Ironwood Pharmaceuticals Inc (IRWD):企業の財務・戦略的SWOT分析
    Ironwood Pharmaceuticals Inc (IRWD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Tetherex Pharmaceuticals Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Tetherex Pharmaceuticals Corp (Tetherex Pharmaceuticals) is a clinical-stage biopharmaceutical company which develops novel medicines for the treatment of inflammation, thrombosis and tumor metastasis. Its lead pipeline product candidate SelK2, a humanized monoclonal antibody targets a cell …
  • National Dentex Corp:企業の戦略的SWOT分析
    National Dentex Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Fortum Corporation:企業の戦略・SWOT・財務情報
    Fortum Corporation - Strategy, SWOT and Corporate Finance Report Summary Fortum Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • WorleyParsons Ltd (WOR):石油・ガス:M&Aディール及び事業提携情報
    Summary WorleyParsons Ltd (WorleyParsons) is a provider of professional services. Its services cover the full lifecycle, from creating new assets to sustaining and enhancing operating assets. The company provides integrated solution for deepwater developments with the associated subsea, pipelines, r …
  • ImpediMed Ltd (IPD):企業の財務・戦略的SWOT分析
    ImpediMed Ltd (IPD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • HDR Inc:企業の戦略的SWOT分析
    HDR Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Sound Energy Plc (SOU):石油・ガス:M&Aディール及び事業提携情報
    Summary Sound Energy Plc (Sound Energy), formerly Sound Oil plc is an upstream oil and gas company that offers exploration and development of oil and gas properties in Europe and Africa. The company holds interests, owns, and operates the Badile permit located in the Piedmont Lombard Basin in northe …
  • HealthCare Global Enterprises Ltd (HCG)-製薬・医療分野:企業M&A・提携分析
    Summary HealthCare Global Enterprises Ltd (HCG), formerly Curie Centre of Oncology Private Ltd is a healthcare service provider that offers medical care and treatment services. The company offers services such as clinical laboratory services, diagnosis services, medical oncology services, radiation …
  • TClarke Plc (CTO):企業の財務・戦略的SWOT分析
    TClarke Plc (CTO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • NOJA Power Switchgear Pty Ltd:企業の戦略的SWOT分析
    NOJA Power Switchgear Pty Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • Helsinn Healthcare SA:企業のM&A・事業提携・投資動向
    Helsinn Healthcare SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Helsinn Healthcare SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M …
  • STATS UK Ltd:企業の戦略的SWOT分析
    STATS UK Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Asn Bank
    Asn Bank - Strategy, SWOT and Corporate Finance Report Summary Asn Bank - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • Wolters Kluwer N.V. (WKL):企業の財務・戦略的SWOT分析
    Wolters Kluwer N.V. (WKL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Frequency Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Frequency Therapeutics Inc (Frequency Therapeutics) is a biotechnology company that develops progenitor cell activation (PCA) therapies. The company’s small molecule drugs are used to activate progenitor cells for restoration of healthy tissue. Its lead program FX-322 is used to recreate sen …
  • Promigas SA ESP (PROMIGAS):企業の財務・戦略的SWOT分析
    Promigas SA ESP (PROMIGAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆